Pre-emptive culling is becoming increasingly questioned as a means of controlling animal diseases, including classical swine fever (CSF). This has prompted discussions on the use of emergency vaccination to control future CSF outbreaks in domestic pigs. Despite a long history of safe use in endemic areas, there is a paucity of data on aspects important to emergency strategies, such as how rapidly CSFV vaccines would protect against transmission, and if this protection is equivalent for all viral genotypes, including highly divergent genotype 3 strains. To evaluate these questions, pigs were vaccinated with the Riemser？ C-strain vaccine at 1, 3 and 5 days prior to challenge with genotype 2.1 and 3.3 challenge strains. The vaccine provided equivalent protection against clinical disease caused by for the two challenge strains and, as expected, protection was complete at 5 days post-vaccination. Substantial protection was achieved after 3 days, which was sufficient to prevent transmission of the 3.3 strain to animals in direct contact. Even by one day post-vaccination approximately half the animals were partially protected, and were able to control the infection, indicating that a reduction of the infectious potential is achieved very rapidly after vaccination. There was a close temporal correlation between T cell IFN-γ responses and protection. Interestingly, compared to responses of animals challenged 5 days after vaccination, challenge of animals 3 or 1 days post-vaccination resulted in impaired vaccine-induced T cell responses. This, together with the failure to detect a T cell IFN-γ response in unprotected and unvaccinated animals, indicates that virulent CSFV can inhibit the potent antiviral host defences primed by C-strain in the early period post vaccination.
References
[1]
van Oirschot JT (2003) Vaccinology of classical swine fever: from lab to field. Vet Microbiol 96: 367–384.
[2]
Suradhat S, Damrongwatanapokin S, Thanawongnuwech R (2007) Factors critical for successful vaccination against classical swine fever in endemic areas. Vet Microbiol 119: 1–9.
[3]
van Oirschot JT (2003) Emergency vaccination against classical swine fever. Dev Biol (Basel) 114: 259–267.
[4]
Vandeputte J, Chappuis G (1999) Classical swine fever: the European experience and a guide for infected areas. Rev Sci Tech 18: 638–647.
[5]
von Ruden S, Staubach C, Kaden V, Hess RG, Blicke J, et al. (2008) Retrospective analysis of the oral immunisation of wild boar populations against classical swine fever virus (CSFV) in region Eifel of Rhineland-Palatinate. Vet Microbiol 132: 29–38.
[6]
Anonymous , Communities OJoE, editor (2001) Council Directive 2001/89/EC. 35 p.
[7]
Stegeman A, Elbers A, de Smit H, Moser H, Smak J, et al. (2000) The 1997–1998 epidemic of classical swine fever in the Netherlands. Vet Microbiol 73: 183–196.
[8]
Greiser-Wilke I, Fritzemeier J, Koenen F, Vanderhallen H, Rutili D, et al. (2000) Molecular epidemiology of a large classical swine fever epidemic in the European Union in 1997–1998. Vet Microbiol 77: 17–27.
[9]
Paton D (2002) The reappearance of Classical Swine Fever in England in 2000. In: A M, editor. Trends in Emerging Viral Infections of Swine. Iowa: Iowa State Press. pp. 153–158.
[10]
Cohen NE, van Asseldonk MAPM, Stassen EN (2007) Social-ethical issues concerning the control strategy of animal diseases in the European Union: A survey. Agriculture and Human Values 24: 499–510.
[11]
Mourits MC, van Asseldonk MA, Huirne RB (2010) Multi Criteria Decision Making to evaluate control strategies of contagious animal diseases. Prev Vet Med 96: 201–210.
[12]
Boklund A, Toft N, Alban L, Uttenthal A (2009) Comparing the epidemiological and economic effects of control strategies against classical swine fever in Denmark. Prev Vet Med 90: 180–193.
[13]
Greiser-Wilke I, Moennig V (2004) Vaccination against classical swine fever virus: limitations and new strategies. Anim Health Res Rev 5: 223–226.
[14]
Anonymous (2009) Animal health safety of fresh meat derived from pigs vaccinated against classical swine fever. Scientific opinion of the panel on animal helalth and welfare. The EFSA Journal 933: 1–15.
[15]
Uttenthal A, Le Potier MF, Romero L, De Mia GM, Floegel-Niesmann G (2001) Classical swine fever (CSF) marker vaccine. Trial I. Challenge studies in weaner pigs. Vet Microbiol 83: 85–106.
[16]
Depner KR, Bouma A, Koenen F, Klinkenberg D, Lange E, et al. (2001) Classical swine fever (CSF) marker vaccine. Trial II. Challenge study in pregnant sows. Vet Microbiol 83: 107–120.
[17]
Floegel-Niesmann G (2001) Classical swine fever (CSF) marker vaccine. Trial III. Evaluation of discriminatory ELISAs. Vet Microbiol 83: 121–136.
[18]
Beer M, Reimann I, Hoffmann B, Depner K (2007) Novel marker vaccines against classical swine fever. Vaccine 25: 5665–5670.
[19]
Uttenthal A, Parida S, Rasmussen TB, Paton DJ, Haas B, et al. (2010) Strategies for differentiating infection in vaccinated animals (DIVA) for foot-and-mouth disease, classical swine fever and avian influenza. Expert Rev Vaccines 9: 73–87.
[20]
Backer JA, Hagenaars TJ, van Roermund HJ, de Jong MC (2009) Modelling the effectiveness and risks of vaccination strategies to control classical swine fever epidemics. J R Soc Interface 6: 849–861.
[21]
Kaden V, Lange B (2001) Oral immunisation against classical swine fever (CSF): onset and duration of immunity. Vet Microbiol 82: 301–310.
[22]
Qui Hau-jiSR-x, Tong Guang-zhi (2006) The Lapinized Chinese Strain Vaccine Against Classical Swine Fever Virus: A Retrospective Review Spanning Half A Century. Agricultural Sciences in China 5: 1–14.
[23]
Kaden V, Glaner M (1982) [Onset and persistence of immunity to swine fever following aerogenic immunization]. Arch Exp Veterinarmed 36: 593–599.
[24]
Dewulf J, Laevens H, Koenen F, Mintiens K, de Kruif A (2004) Efficacy of E2-sub-unit marker and C-strain vaccines in reducing horizontal transmission of classical swine fever virus in weaner pigs. Prev Vet Med 65: 121–133.
[25]
Dahle J, Liess B (1995) Assessment of safety and protective value of a cell culture modified strain “C” vaccine of hog cholera/classical swine fever virus. Berl Munch Tierarztl Wochenschr 108: 20–25.
[26]
Biront P, Leunen J, Vandeputte J (1987) Inhibition of virus replication in the tonsils of pigs previously vaccinated with a Chinese strain vaccine and challenged oronasally with a virulent strain of classical swine fever virus. Vet Microbiol 14: 105–113.
[27]
Suradhat S, Damrongwatanapokin S (2003) The influence of maternal immunity on the efficacy of a classical swine fever vaccine against classical swine fever virus, genogroup 2.2, infection. Vet Microbiol 92: 187–194.
[28]
Chen N, Hu H, Zhang Z, Shuai J, Jiang L, et al. (2008) Genetic diversity of the envelope glycoprotein E2 of classical swine fever virus: recent isolates branched away from historical and vaccine strains. Vet Microbiol 127: 286–299.
[29]
Zhu Y, Shi Z, Drew TW, Wang Q, Qiu H, et al. (2009) Antigenic differentiation of classical swine fever viruses in China by monoclonal antibodies. Virus Res 142: 169–174.
[30]
Parchariyanon S, Inui K, Damrongwatanapokin S, Pinyochon W, Lowings P, et al. (2000) Sequence analysis of E2 glycoprotein genes of classical swine fever viruses: identification of a novel genogroup in Thailand. Dtsch Tierarztl Wochenschr 107: 236–238.
[31]
Zhang F, Yu M, Weiland E, Morrissy C, Zhang N, et al. (2006) Characterization of epitopes for neutralizing monoclonal antibodies to classical swine fever virus E2 and Erns using phage-displayed random peptide library. Arch Virol 151: 37–54.
[32]
Parchariyanon S, Damrongwatanapokin S, Pinyochon W, Inui K, Blacksell S, et al. (2001) Diversity of Classical Swine Fever Virus in Thailand: Antigenic and Vaccine efficiency studies. J Thai Vet Med Assoc 52: 9–18.
[33]
Terpstra C, Woortmeyer R, Barteling SJ (1990) Development and properties of a cell culture produced vaccine for hog cholera based on the Chinese strain. Dtsch Tierarztl Wochenschr 97: 77–79.
[34]
Suradhat S, Intrakamhaeng M, Damrongwatanapokin S (2001) The correlation of virus-specific interferon-gamma production and protection against classical swine fever virus infection. Vet Immunol Immunopathol 83: 177–189.
[35]
Ceppi M, de Bruin MG, Seuberlich T, Balmelli C, Pascolo S, et al. (2005) Identification of classical swine fever virus protein E2 as a target for cytotoxic T cells by using mRNA-transfected antigen-presenting cells. J Gen Virol 86: 2525–2534.
[36]
Rau H, Revets H, Balmelli C, McCullough KC, Summerfield A (2006) Immunological properties of recombinant classical swine fever virus NS3 protein in vitro and in vivo. Vet Res 37: 155–168.
[37]
Suradhat S, Sada W, Buranapraditkun S, Damrongwatanapokin S (2005) The kinetics of cytokine production and CD25 expression by porcine lymphocyte subpopulations following exposure to classical swine fever virus (CSFV). Vet Immunol Immunopathol 106: 197–208.
[38]
Pauly T, Elbers K, Konig M, Lengsfeld T, Saalmuller A, et al. (1995) Classical swine fever virus-specific cytotoxic T lymphocytes and identification of a T cell epitope. J Gen Virol 76(Pt 12): 3039–3049.
[39]
Graham SP, Everett HE, Johns HL, Haines FJ, Rocca SA, et al. (2009) Characterisation of virus-specific peripheral blood cell cytokine responses following vaccination or infection with classical swine fever viruses. Vet Microbiol.
[40]
Sandvik T, Drew T, Paton D (2000) CSF virus in East Anglia: where from? Vet Rec 147: 251.
[41]
Drew TW (2008) Classical Swine Fever (hog cholera). OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (mammals, birds and bees) Sixth ed. Paris, France: World Organisation for Animal Health (OIE). pp. 1092–1106.
[42]
Mittelholzer C, Moser C, Tratschin JD, Hofmann MA (2000) Analysis of classical swine fever virus replication kinetics allows differentiation of highly virulent from avirulent strains. Vet Microbiol 74: 293–308.
[43]
Everett H, Salguero FJ, Graham SP, Haines F, Johns H, et al. (2009) Characterisation of experimental infections of domestic pigs with genotype 2.1 and 3.3 isolates of classical swine fever virus. Vet Microbiol.
[44]
Cha SH, Choi EJ, Park JH, Yoon SR, Kwon JH, et al. (2007) Phylogenetic characterization of classical swine fever viruses isolated in Korea between 1988 and 2003. Virus Res 126: 256–261.
[45]
Sakoda Y, Ozawa S, Damrongwatanapokin S, Sato M, Ishikawa K, et al. (1999) Genetic heterogeneity of porcine and ruminant pestiviruses mainly isolated in Japan. Vet Microbiol 65: 75–86.
[46]
Pan CH, Jong MH, Huang TS, Liu HF, Lin SY, et al. (2005) Phylogenetic analysis of classical swine fever virus in Taiwan. Arch Virol 150: 1101–1119.
[47]
Deng MC, Huang CC, Huang TS, Chang CY, Lin YJ, et al. (2005) Phylogenetic analysis of classical swine fever virus isolated from Taiwan. Vet Microbiol 106: 187–193.
[48]
Weesendorp E, Backer J, Stegeman A, Loeffen W (2010) Transmission of classical swine fever virus depends on the clinical course of infection which is associated with high and low levels of virus excretion. Vet Microbiol 147: 262–273.
[49]
Koenig P, Hoffmann B, Depner KR, Reimann I, Teifke JP, et al. (2007) Detection of classical swine fever vaccine virus in blood and tissue samples of pigs vaccinated either with a conventional C-strain vaccine or a modified live marker vaccine. Vet Microbiol 120: 343–351.
[50]
Blome S, Gabriel C, Staubach C, Leifer I, Strebelow G, et al. (2011) Genetic differentiation of infected from vaccinated animals after implementation of an emergency vaccination strategy against classical swine fever in wild boar. Vet Microbiol.
[51]
Tarradas J, Argilaguet JM, Rosell R, Nofrarias M, Crisci E, et al. (2010) Interferon-gamma induction correlates with protection by DNA vaccine expressing E2 glycoprotein against classical swine fever virus infection in domestic pigs. Vet Microbiol 142: 51–58.
